The new technologies of radionuclide therapy are allowing for personalized treatment of various forms of cancer. Learn more about the clinical utility of these procedures and earn free CE credit.
Welcome to our Healthcare Provider portal. Everything you need to understand the advantages and applications of nuclear medicine and molecular imaging in your practice. Find out more about ordering the right test for the right patient at the right time.
Molecular imaging is a type of medical imaging that provides detailed pictures of what is happening inside the body at the molecular and cellular level. Where other diagnostic imaging procedures—such as x-rays, computed tomography (CT) and ultrasound—offer pictures of physical structure, molecular imaging allows physicians to see how the body is functioning and to measure its chemical and biological processes.
Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, the radiopharmaceuticals are detected by special types of cameras that work with computers to provide very precise pictures of the area of the body being imaged. Nuclear medicine can also be used to treat certain types of cancer and other diseases.
Molecular imaging offers unique insights into the human body that enable physicians to personalize patient care. In terms of diagnosis, molecular imaging is able to:
SNMMI has created guidelines to identify those elements of the procedure that are most important in obtaining a high-quality examination, Appropriate Use Criteria (AUC), and is working towards optimizing dose.
The SNMMI PET Center of Excellence has created a go-to resource with in-depth ordering information and printable materials related to PET and PET/CT, including:
SNMMI is dedicated to providing the community with access to the most knowledgeable and experienced speakers in the field of nuclear medicine and molecular imaging. As part of the new Outreach Program, SNMMI is working to enhance relationships with relevant societies and patient organizations. We have created a pool of speakers who can speak at your next meeting. Please complete the form below to request a speaker.
SNMMI is happy to report that Baltimore is now calm and things are returning to normal. The Inner Harbor area, where the SNMMI Annual Meeting will take place, has not been affected by the unrest. SNMMI is looking forward to a great meeting June 6-10.
May 4, 2015 - A recent study reported in The Journal of Nuclear Medicine compared use of the novel Ga-68-PSMA-ligand PET/CT with other imaging methods and found that it had substantially higher detection rates of prostate-specific membrane antigen (PSMA) in patients with biochemical recurrence after radical prostatectomy. Discovering a recurrence early can strongly influence further clinical management, so it is especially noteworthy that this hybrid PSMA-ligand identified a large number of positive findings in the clinically important range of low PSA-values (<0.5ng/mL).
Brain metastases are common in human epidermal growth factor receptor (Her)-2-positive breast cancer. Drug access to brain metastases and normal brain is key to management of cranial disease.
(MI: Making a Difference)
The use of myocardial perfusion imaging (MPI) has spiked over the past four decades and along with it individual patient dose. A comprehensive effort to reduce that dose could reduce unnecessary procedures and reduce the risk of downstream cancers, according to a meta-analysis published in the April issue of the Journal of Nuclear Medicine.
(MI: Making a Difference)
Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the National Cancer Institute (NCI) held a joint workshop—NCI-SNMMI Workshop on Targeted Radionuclide Therapy—on October 24-25, 2014, at the National Institutes of Health (NIH) in Bethesda, Md.